PAG, partners to acquire controlling stake in Optimus Drugs for Rs 2,000 crore
''The businesses of the two companies are highly complementary and will provide a solid foundation for the platform to make further acquisitions,'' it said.
New Delhi: A consortium of private equity funds led by PAG will be acquiring a controlling stake in Hyderabad-based pharma company Optimus Drugs for Rs 2,000 crore, a statement said on Wednesday.
The other partners in the consortium include CX Partners and Samara Capital, while PAG, an alternate investment firm, is leading the investment as part of its private equity (PE) strategy, it added.
The 2004-founded Optimus Drugs is a vertically integrated manufacturer of pharmaceutical products including advanced intermediates, active pharmaceutical ingredients (APIs) and finished drugs. It exports more than 100 drug products to 40 countries at present.
Read also: COVID: Optimus Pharma submits phase 3 trials interim result for Molnupiravir capsules
This is the second acquisition by the PE consortium's API platform, Sekhmet Pharmaventures, after acquiring a controlling stake in Chennai-based API manufacturer Anjan Drugs in 2020, the statement said.
''The businesses of the two companies are highly complementary and will provide a solid foundation for the platform to make further acquisitions,'' it said.
Read also: Optimus Pharma gets tentative USFDA approval for Brexpiprazole Tablets
PAG, which has invested USD 580 million in private equity deals in India as of end-2021, feels Optimus is a clear leader in research and development, manufacturing, and intellectual property management, its head of India private equity Nikhil Srivastava said.
''The combined experience of PAG, CX Partners and Samara will help Optimus become a leading player in the global API industry, and further our mission of ensuring better health outcomes for all,'' Optimus' founder and managing director D Srinivas Reddy said.
Read also: Optimus Pharma seeks DCGI nod to produce generic version of Molnupiravir
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.